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Summary
Background Glucocorticoids (GCs) are first-line treatment for keloid disease (KD)
but are limited by high incidence of resistance, recurrence and undesirable side-
effects. Identifying patient responsiveness early could guide therapy.
Methods Nineteen patients with KD were recruited at week 0 (before treatment) and
received intralesional steroids. At weeks 0, 2 and 4, noninvasive imaging and biop-
sies were performed. Responsiveness was determined by clinical response and a sig-
nificant reduction in vascular perfusion following steroid treatment, using full-field
laser perfusion imaging (FLPI). Responsiveness was also evaluated using (i) spec-
trophotometric intracutaneous analysis to quantify changes in collagen and melanin
and (ii) histology to identify changes in epidermal thickness and glycosaminogly-
can (GAG) expression. Biopsies were used to quantify changes in glucocorticoid
receptor (GR) expression using quantitative reverse transcriptase polymerase chain
reaction, immunoblotting and immunohistochemistry.
Results At week 2, the FLPI was used to separate patients into steroid responsive
(n = 12) and nonresponsive groups (n = 7). All patients demonstrated a signifi-
cant decrease in GAG at week 2 (P < 005). At week 4, responsive patients
exhibited significant reduction in melanin, GAG, epidermal thickness (all
P < 005) and a continued reduction in perfusion (P < 0001) compared with
nonresponders. Steroid-responsive patients had increased GR expression at base-
line and showed autoregulation of GR compared with nonresponders, who
showed no change in GR transcription or protein.
Conclusions This is the first demonstration that keloid response to steroids can be
measured objectively using noninvasive imaging. FLPI is a potentially reliable tool
to stratify KD responsiveness. Altered GR expression may be the mechanism
gating therapeutic response.
What’s already known about this topic?
• Steroids are used as first-line treatment for keloid disease, but response is variable
with apparent steroid responders and nonresponders.
• It remains unclear whether steroid responsiveness is due to an intrinsic difference
in the mechanism of the glucocorticoid receptor (GR) action or reduced sensitivity
to the steroid itself.
What does this study add?
• We show for the first time the utility of noninvasive imaging techniques in strati-
fying steroid responsiveness in patients treated with steroids.
• GR expression increased significantly in keloid tissue. Increased GR expression also
correlated with an increased response to steroid treatment.
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• Steroid responders show a significant decrease in GR transcript and protein
2 weeks after steroid treatment (P < 005), which was not evident in steroid-resis-
tant patients.
Keloid disease (KD) is a fibroproliferative disorder of unknown
aetiopathogenesis. Lesions arise as a result of skin injury or
infection, although it may not be possible to identify the causa-
tive event, and lesions typically extend beyond the original
wound boundary, commonly recurring after excision.1 These
scars have an aesthetic, physical and psychological effect on the
patient and adversely impact on patients’ quality of life.2
Management of keloid disease is ill defined and a variety of
treatment strategies have been recommended. The interna-
tional guidelines on management of keloid scarring have
recommended the use of corticosteroids as a first-line
therapy.3 However, not all keloid scars respond to steroid
treatment and there is a 50% recurrence rate.3 Most treatment
algorithms require multiple serial injections of intralesional
steroid, which are not only painful but can also cause a num-
ber of steroid-induced side-effects, including skin atrophy,
hypopigmentation, telangiectasia, ulceration and, rarely, Cush-
ing syndrome.4 The partial response to steroid therapy in a
significant number of patients and the commonly reported
side-effects indicate that intralesional steroid injections should
be used with caution. Thus, an early, objective assessment of
steroid responsiveness would be very useful.
Synthetic steroids are commonly used in the management
of KD and include dexamethasone, methylprednisolone and
triamcinolone (TAC).5,6 Steroids used to treat KD act by
decreasing inflammation, reducing lesional volume and
erythema.7 In vitro studies have shown that certain changes
are induced in lesions treated with corticosteroids, including
reduction in the quantity of extracellular matrix proteins,
suppression of the pro-a1 collagen gene, and reduction in
both vascular endothelial growth factor and angiogenesis.7–11
Changes in the architecture of KD have been documented
with an improvement in the organization of collagen bun-
dles as well as a degeneration of the collagen nodules.12
Triamcinolone and other glucocorticoids (GCs) are reliant
upon the functioning of the glucocorticoid receptor (GR), a
member of the nuclear receptor superfamily.6 GR is expressed
in most cell types and is essential for regulating a range of phys-
iological processes, most notably immunity and metabolism.6
To date, little is known about the underlying mechanisms caus-
ing steroid resistance in KD, and there are currently no methods
to objectively track steroid responses longitudinally.
Materials and methods
Patient recruitment and tissue collection
Ethical approval for this study was obtained from the South
Manchester Research Ethics Committee, Manchester, U.K. The
study adhered to Declaration of Helsinki principles and written
informed consent was obtained from all patients. Twenty
patients (Fig. 1) with untreated keloids were recruited from
the University Hospital of South Manchester National Health
Service Foundation Trust. A full medical history was taken and
the scar photographed. Baseline noninvasive imaging of the
scar was performed using spectrophotometric intracutaneous
Week 0
Patient recruitment 
(n = 20)
Noninvasive imaging
Biopsy
Steroid injection
Week 2
Noninvasive imaging
Biopsy (n = 19)
Week 4
Noninvasive imaging
Biopsy (n = 19)
Week 0
qRT-PCR
Western blot
GR IHC
GAG
Clinical Laboratory
Week 2
qRT-PCR
Western blot
GR IHC
GAG
Week 4
qRT-PCR
Western blot
GR IHC
GAG
Stratify by 
response
Patient 
ID
Sex Age 
(years)
Ethnicity Location Responder/
nonresponder
Str1 M 38 Black Afro-
Caribbean
Right scapula Nonresponder
Str2 M 39 White Sternum Responder
Str3 F 19 Asian Sternum Nonresponder
Str4 M 63 White Left scapula Responder
Str5 F 28 Asian Right thigh Responder
Str6 M 28 White Sternum Responder
Str7 M 32 White Sternum Responder
Str8 M 28 Black Afro-
Caribbean
Back Nonresponder
Str9 M 28 Asian/other Sternum Responder
Str10 F 55 Black Afro-
Caribbean
Left arm Nonresponder
Str11 M 23 White Sternum Nonresponder
Str12 F 78 White Sternum Responder
Str13 F 28 White Sternum Responder
Str14 F 21 White Sternum Responder
Str15 M 34 White Right arm Responder
Str16 F 17 White Left arm Nonresponder
Str17 M 36 Asian Abdomen Responder
Str19 F 28 Asian Sternum Nonresponder
Str20 M 28 White Sternum Responder
(a)
(b)
Fig 1. (a) Experimental design. qRT-PCR, quantitative reverse
transcriptase polymerase chain reaction; GR IHC, glucocorticoid
receptor immunohistochemistry; GAG, glycosaminoglycan. (b) Patient
demographics. M, male; F, female.
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analysis (SIAscopy)13–15 (Astron Clinica, Cambridge, U.K.)
and full-field laser perfusion imaging (FLPI; Moor Instru-
ments, Axminster, U.K.)13,14,16–18 (Fig. 2). Following imag-
ing, a 4-mm punch biopsy of the keloid scar was taken under
local anaesthetic (week 0). Subsequently, participants under-
went treatment with an intralesional injection of 10 mg ml1
TAC, using a fine bore needle, inserted horizontally into the
keloid tissue and gradually withdrawn while simultaneously
injecting until the scar became uniformly blanched (to nor-
malise for different scar volumes) with a maximum dose of
5 mg at any one site.
Nineteen patients (one declined further follow-up) returned
for evaluation at two and 4 weeks when scars were assessed
using noninvasive imaging and a further 4-mm punch biopsy
was taken from the same scar. Biopsies were bisected and
stored in the appropriate medium according to experimental
requirements. Samples were stored in compliance with the
Human Tissue Act of 2004.
Full-field laser perfusion imaging
Laser Doppler imaging, such as FLPI, is a validated technique
which utilizes a monochromatic laser. Dynamic components of
the skin, e.g. red blood cells, cause variations in the laser speckle
contrast and a shift in the laser wavelength. Based on these
changes, the instrument is able to assess dermal blood flow.19,20
The FLPI was positioned 40 cm from the scar and used to
take 10 separate images over 10 s and the average flux per
second was calculated. Perfusion of the scar was normalized to
the surrounding uninvolved skin (defined as skin without
pathology which was at least 10 cm away from the scar of
interest). Fold change was calculated post-treatment at week 2
compared with the level before treatment. Perfusion was also
measured at week 4 to determine if reductions in perfusion
continued or returned to baseline levels.
Spectrophotometric intracutaneous analysis
Changes in collagen and melanin were measured using
SIAscopy as described previously.13,14 SIAscopy measures the
absorption and reflection of visible and infrared light and can
penetrate the skin to a depth of 2 mm. The reflected light is
analysed giving quantitative data regarding the concentration
of melanin and collagen within the skin.21,22 The SIAscope
was placed within the centre of the scar for 10 s and applied
under gentle pressure to avoid blanching of the skin.
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Fig 2. Flux profiling to stratify patient responses to steroid treatment. Keloids from 19 patients were imaged using full-field laser perfusion
imaging. In each case, perfusion of keloid scar was normalized to the surrounding normal tissue. (a) Representative flux profiles are shown. Areas
of high flux are red and low flux are blue. (b) Steroid-dependent change in perfusion at week 2. Those who demonstrated reductions (below the
line) in flux were designated responsive patients (RPs) and those who did not (above the line) were designated nonresponsive patients (nRPs). (c)
Perfusion at week 0 for RPs (n = 12) and nRPs (n = 7). (d) Perfusion at week 4 for RPs and nRPs. *P < 005.
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Histology
Tissues were fixed in buffered formalin and dehydrated through
serial alcohol prior to immersion in xylene and wax embedding.
Three sections were used per biopsy. Tissue sections (4-lm
thick) were dewaxed, and then stained with haematoxylin and
eosin.23 Images were taken using the Keyence BioImager (Key-
ence, Itasca, IL, U.S.A.) and randomized. Six representative mea-
surements of the epidermis were taken per section, using Image
J (Wayne Rasband, NIH, Bethesda, MD, U.S.A.), and averaged.
Further tissue sections (4-lm thick) were dewaxed, stained
with 025% Alcian blue 8GX (diluted in 05 mol L1 HCl;
60 min). Serial images were analysed with Image J, and image
intensity/5 lm from the dermal epidermal junction extending
300 lm into the dermis was calculated. Data was plotted
using Microsoft Excel (Microsoft Corporation, Redmond, WA,
U.S.A.) and GraphPad Prism 4.0 (GraphPad Software, La Jolla,
CA, U.S.A.).
Quantitative reverse transcriptase polymerase chain
reaction
Biopsies were homogenized using TissueLyser II (Qiagen,
Venlo, the Netherlands) in Trizol. RNA extraction, cDNA syn-
thesis and quantitative reverse transcriptase polymerase chain
reaction (qRT-PCR) was carried out as described previ-
ously.24,25 Each sample was analysed for both target (GR) and
reference genes [RPL32 (60S ribosomal protein L32) and SDHA
(succinate dehydrogenase complex, subunit A)] (Table 1).
The raw data for each reaction was analysed by using the
comparative cycle threshold value (CT value) for both the ref-
erence genes and the candidate target gene and fold change
was calculated. For comparison, normal skin samples (n = 5)
were obtained from patients without keloids and compared
with keloid lesions before treatment.
Immunoblotting
Snap-frozen biopsy sections were homogenized in radio-
immunoprecipitation assay lysis buffer (containing protease-
and phosphatase-inhibitor cocktails; Sigma-Aldrich, St Louis,
MO, U.S.A.) and cleared by centrifugation, and protein con-
centrations were determined by the Bradford protein assay
(BioRad, Hemel Hempstead, U.K.).26 Twenty lg of protein
was electrophoresed on 4–12% Tris glycine gels (Invitrogen,
Carlsbad, CA, U.S.A.) and transferred to 05-lm nitrocellulose
membranes. Membranes were blocked (NaCl 015 mol L1,
1% dried milk, 01% Tween 20) and incubated in primary
antibody overnight (mouse monoclonal GR antibody-clone
41, diluted 1 : 2000; BD Biosciences, San Jose, CA, U.S.A)
(Table 2). Membranes were washed (88 mmol L1 Tris pH
78, 025% dried milk, 01% Tween 20) and incubated with
anti-mouse horse radish peroxidase (1 : 5000 dilution).
Immunoreactive signals were visualized using chemilumines-
cent substrate (GE Healthcare, Little Chalfont, U.K.) reagent
and band density quantified using image J.
Immunohistochemistry
Four-micron-thick tissue sections were dewaxed, rehydrated
and permeabilized with 05% Triton X-100 in Tris buffered sal-
ine (TBS) before quenching in 01% hydrogen peroxidase for
30 min. Sections were blocked for 1 h in 3% goat serum in TBS
and primary GR antibody (Thermo Scientific, Waltham, MA,
U.S.A.) (Table 1) applied overnight at 4 °C. Slides were washed
with TBS and then incubated with goat anti-rabbit-biotin (ABC
Elite kit; Vector Laboratories, Peterborough, U.K.) (Table 3) for
30 min and subsequently washed with TBS for 5 min. Avidin-
biotin reagent was applied for 30 min and washed again with
TBS for 5 min before Vector SG chromogen (Vector Laborato-
ries) was applied. Counterstaining of the nucleus was carried
out using Nuclear Fast Red (Vector Laboratories). Sections were
randomized, blinded and then graded on a five point scale of
0 = no staining to 4 = maximal GR staining.27
Statistical analysis
Statistical analysis was carried out using SPSS 160 (IBM;
Armonk, NY, U.S.A.). Kruskal–Wallis one-way ANOVA was used
to calculate the statistical difference between time points
Table 1 List of primary antibodies used in this study
Antibody Host species Isotype Clone In-cell Western dilution IHC-dilution Source
Antiglucocorticoid receptor a Rabbit IgG – – 1 : 50 Thermo Scientific
Antiglucocorticoid receptor Mouse IgG1 41 1 : 2000 - BD Bioscience
Anti-a-tubulin Mouse IgG1 DMA1 1 : 5000 - Sigma-Aldrich
IHC, immunohistochemistry.
Table 2 List of secondary antibodies used in this study
Antibody
Host
species Isotype
Active
against Source
ECL Mouse,
horseradish
peroxidase-linked
whole Ab
Sheep IgG Mouse GE Healthcare
Vectastain Elite
ABC Kit
Goat IgG Rabbit Vector
Laboratories
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within responders and nonresponders. Mann–Whitney U-tests
were used to calculate differences between responders and
nonresponders at specific time points and statistical differences
between the keloid lesion, clinically normal skin and skin of
patients without keloids for qRT-PCR. Graphs were plotted
using GraphPad 5.0 (GraphPad Software).
Results
Clinical findings
As summarized in Fig. 1a, keloid scars from 20 patients were
imaged by noninvasive imaging, punch-biopsied and injected
with intralesional steroid (one patient declined further
involvement following the initial biopsy). Fold changes in
perfusion pre- and poststeroid treatment were calculated at
week 2 (Fig. 2a) for the 19 remaining participants (demo-
graphics in Fig. 1b). Twelve of the 19 patients showed a
decrease in vascular perfusion (Fig. 2b) and they were desig-
nated as responsive, with the remaining seven being non-
responsive (Fig. 2b).
Baseline perfusion between both responsive patients (RPs)
and nonresponsive patients (nRPs) showed no statistically sig-
nificant difference; however, a decrease in perfusion in RPs
was still evident at week 4 (Fig. 2d; Table 4).
In vivo evaluation of glucocorticoid responsiveness in
keloid scars using noninvasive imaging
SIAscopy was used to measure changes in collagen and mela-
nin. Baseline comparisons at week 0 showed no significant
difference between RPs and nRPs in either collagen or mela-
nin, implying similar phenotypic characteristics of scars in
both groups (Fig. 3b and d).
Responsive patients demonstrated a significant decrease in
melanin at weeks 2 and 4 (P < 005). In contrast, no signifi-
cant change was observed in nRPs at either time point (Fig 3e).
Compared with nRPs, RPs showed a significant decrease in
melanin at week 4 (P < 005) (Fig. 3; Tables 5 and 6).
RPs demonstrated an increase in collagen at weeks 2 and 4
(P < 005), which was not evident in nRPs (Fig. 3c). A signif-
icant increase in collagen was seen in RPs at week 4 compared
with nRPs (P < 005) (Fig. 3c; Tables 5 and 6).
Histological assessment of glucocorticoid responsiveness
in keloid scars
Alcian blue staining was used to quantify glycosaminoglycan
(GAG) expression as a measure of histological responsiveness.
There was no significant difference between the two groups
prior to steroid treatment (Fig 4a). RPs demonstrated a signifi-
cant decrease in GAG staining at both weeks 2 and 4
(P < 005) compared with before treatment. In nRPs, there
was a significant reduction only at week 2 (P < 005)
(Fig. 4b).
Epidermal atrophy is a well-known side-effect of GCs.28
Epidermal thickness (ET), was quantified in sections stained
with haematoxylin and eosin and showed no significant differ-
ence between RPs and nRPs at week 0 (Fig. 4 c,d). In RPs, ET
did not change at week 2 but showed a significant decrease
by week 4 (P < 005); nRPs showed no significant change at
either time point (Fig. 4 c,d,e; Tables 5 and 6).
Table 3 List of primers used in this study
Gene/primer Gene ID Sequence 50 to 30 Amplicon size (bp)
GR-L nm_001018077.1 GGGTGGAGATCATATAGACAATCAA 94
GR-R nm_001018077.1 ACATGCAGGGTAGAGTCATTCTC 94
RPL32 – L nm_000994.3 GAAGTTCCTGGTCCACAACG 76
RPL32 – R nm_000994.3 GAGCGATCTCGGCACAGTA 76
SDHA – L nm_004168.2 AGAAGCCCTTTGAGGAGCA 88
SDHA – R nm_004168.2 CACGGGTCTATATTCCAGAGTGA 88
Table 4 Baseline comparison of responders and nonresponders
Week 0 [median (IQR)]
Responders Nonresponders Significance between groupsa
Melanin 1477 (9866–4314) 2180 (3511–6396) P = NS
Collagen 2256 (1608–2727) 2825 (1967–3923) P = NS
Glycosaminoglycan 11 130 (10 370–14 490) 12 000 (11 430–12 450) P = NS
Epidermal thickness 7662 (6282–8809) 5855 (4615–6970) P = NS
FLPI 2039 (1381–2617) 1547 (3497–1979) P = NS
Glucocorticoid receptor transcription 002668 (001651–05966) 001425 (0009958–001726) P = 00312
Glucocorticoid receptor immunohistochemistry 25 (1875–2714) 1278 (1107–1792) P = 00176
Glucocorticoid receptor western blot 06420 (04324–07379) 03419 (03301–05797) P = 02286
IQR, interquartile range; FLPI, full-field laser perfusion imaging. aMann–Whitney U-test.
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Glucocorticoid receptor expression in responders vs.
nonresponders
Immunohistochemistry revealed that GR staining was highest
in the epidermal layer, with strong staining in fibroblasts of
the papillary dermis layer, and minimal staining in the reticu-
lar dermis layer (Fig. 5a). This ratio was consistent across all
sections examined. Scoring sections on a four-point scale sug-
gested that GR expression was significantly higher in RPs at
week 0 compared with nRPs (P < 005) (Fig. 5b; Tables 5
and 6). RPs demonstrated a significant reduction in GR protein
at week 2 (P < 005), which returned to baseline by week 4,
whereas nRPs did not show any significant difference
(Fig. 5c).
Closer examination of GR subcellular localization suggested
that in RPs at week 0, GR had a heterogeneous subcellular
distribution localizing to the nucleus of some cells and the
cytoplasm in others. At week 2, GR was identifiable only in
cell nuclei, a marker of activation (Fig. 5d, indicated by aster-
isks). In nRPs, GR showed a comparable heterogeneous distri-
bution, but again there was evidence of immune cell
infiltration after steroid treatment (Fig 5d, indicated by arrow-
heads).
To more readily quantify GR expression, GR transcription
was measured by qRT-PCR. At week 0, consistent with immu-
nohistological analysis, RPs had significantly higher levels of
GR transcription than nRPs (Fig 6a). RPs also had a significant
decrease in GR transcription at weeks 2 and 4 (P < 001 and
P < 005, respectively). nRPs showed no significant change at
any time point (Fig. 6b; Tables 5 and 6). This finding was
further supported by immunoblotting (Fig. 6c), which
showed increased GR protein in RPs at week 0 (Fig. 6d), and
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Fig 3. Clinical response to intralesional steroid injections. (a) Representative photographs of keloid scars of responsive patients (RPs) and
nonresponsive patients (nRPs) at week 0 and week 4. Scale bar 2 cm. (b–e) Spectrophotometric intracutaneous analysis was used to quantify
collagen and melanin chromophores. (b) Collagen chromophore at week 0 for RPs (n = 12) and nRPs (n = 7). (c) Steroid-dependent change in
collagen chromophore at weeks 2 and 4. (d) Melanin chromophore at week 0 for RP (n = 12) and nRP (n = 7). (e) Steroid-dependent fold
change in melanin chromophore at weeks 2 and 4. *P < 005.
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significant downregulation of GR protein in RPs (P < 005)
but not nRPs at week 2 (Fig. 6e). Interestingly, a significant
increase in GR transcription was seen in keloid lesions com-
pared with skin from patients without keloids (P < 001),
implying that GR expression is upregulated in RPs rather
than downregulated in nRPs (Fig. 6f).
Discussion
This study has used, for the first time, both objective nonin-
vasive and experimental techniques to distinguish between
GC-responsive keloid cases and nonresponders. FLPI was used
to measure change in perfusion as an early and sensitive
marker of response to steroid treatment that would pre-date
any clinical improvement.13,29 Clinically, RPs demonstrated a
significant decrease in melanin and an increase of collagen,
which was not seen in nRPs. This increase in collagen was
unexpected, as steroids are known to decrease collagen turn-
over. It was postulated that the increase in collagen detected
by SIAscopy was correlated to epidermal thinning. The SIAs-
copy is limited by its ability to penetrate to 2 mm into the
skin. In RPs, we have demonstrated epidermal thinning and,
as such, SIAscopy can penetrate deeper into the papillary der-
mis and therefore detect a greater volume of collagen. In
addition, steroid inhibition of GAG may contribute to the
apparent increase in collagen by increasing the density of
collagen fibres within the dermis.30,31
RPs showed a significant decrease in melanin. This is con-
sistent with clinical observations that steroids cause hypopig-
mentation, particularly in darker-skinned individuals.12,32 GC
inhibition of melanogenesis has been attributed to a number
of cellular mechanisms and the arrest of the melanocyte cell
cycle.33 Melanocytes express high levels of GR and when
incubated with TAC produce a 30% reduction in cell
growth.34
Glucocorticoids mediate their action through the GR, yet a
paucity of information exists on GR in both keloid andTa
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Table 6 Mann–Whitney U-test comparing responders and
nonresponders at weeks 2 and 4 for all parameters
Proteins analysed
Week 2 responders
vs. nonresponders
Week 4 responders
vs. nonresponders
Melanin P = 04943 P = 00140
Collagen P = 01471 P = 00093
Glycosaminoglycan P = 08857 P = 06324
Epidermal thickness P = 1000 P = 00381
Glucocorticoid
receptor qRT-PCR
P = 03414 P = 00229
Glucocorticoid
receptor western blot
P = 00571 P = 07000
Glucocorticoid
receptor
immunostaining
P = 00012 P = 03290
qRT-PCR, quantitative reverse transcriptase polymerase chain
reaction.
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healthy, normal skin. Gadson et al. demonstrated that receptors
derived from keloid tissue do not differ from those derived
from healthy tissue in terms of steroid specificity, dissociation
constant, total number of binding sites or nuclear binding of
GR complexes.34 We have reported that GR expression in RPs
before treatment was significantly more than in nRPs and that
levels significantly decreased in both mRNA and protein post-
GC treatment. Through a process of autoregulation, GCs
downregulate steady-state expression of GR in both cell lines
and tissue.35–39 HeLa cells treated long term with dexametha-
sone showed a 50% downregulation in the level of the GR in
both protein and mRNA levels.40 This decrease in both mRNA
and protein seen previously implies that an essential compo-
nent in the downregulation of GR protein lies at the level of
mRNA.36
We have shown that GR levels in RPs were significantly
higher than nRPs at baseline. A decrease in the expression of
GR in RPs has been reported in asthma and systemic
lupus.41,42 GR beta (shown to affect steroid resistance) is an
alternate isoform, which differs from GR alpha at its carboxy
terminal.43 Oakley et al. demonstrated that expression of GR
beta in cells inhibits GR-mediated gene expression and is a
dominant negative inhibitor of GR alpha.42 Thus, the reduced
expression of GR in nRPs and the lack of GR downregulation
following GC treatment may represent the presence of GR
beta. The expression of this isoform has been seen in mRNA
from cultured keloid fibroblasts.24
Interestingly, GR transcription was significantly higher in
KD than in skin from patients without keloids. Supporting our
results, Syed et al. showed that cultured keloid fibroblasts
expressed higher levels of GR than normal skin fibroblasts. In
recent years, several papers have highlighted that keloid dis-
ease represents an inflammatory condition associated with
increased expression of B cells, T cells and mast cells.44 In
addition, expression of transforming growth factors and
nuclear factor kappa beta (NF-jB), known to mediate inflam-
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Fig 4. Histological measurement of epidermal thickness and glycosaminoglycan (GAG) content. (a, b) Alcian blue staining was used to quantify
GAGs. (a) GAG content at week 0 for responsive patients (RPs) (n = 12) and nonresponsive patients (nRPs) (n = 7). (b) Steroid-dependent
change in GAG content at weeks 2 and 4. (c–e) Sections were stained with haematoxylin and eosin, and epidermal thickness quantified at 10
different positions across each section. (c) Representative images are shown. White line indicates epidermal thickness. (d) Epidermal thickness at
week 0 for RPs (n = 12) and nRPs (n = 7). (e) Steroid-dependent change in epidermal thickness at weeks 2 and 4. *P < 005.
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mation, is known to be elevated in keloid fibroblasts com-
pared with normal skin fibroblasts.45,46 An in vivo study by
Schottelius et al. showed an increased expression of GR in
inflammatory bowel disease and hypothesized an intrinsic
mechanism to counteract elevated levels of NF-jB by
downregulating its expression through interaction of GR with
NF-jB-p65 and upregulating the expression of NF-jB
inhibitory molecule.24,47
In clinical practice, keloids are treated by a monthly
injection of TAC until resolution of the clinical symptoms
of the KD. However, a number of patients show resistance
to treatment which is not only frustrating for the clinician
but is painful with potential undesirable side-effects for the
patient. Steroids should ideally be employed in patients in
whom responsiveness is demonstrated. Nonresponders
should be considered for alternative treatments.48,49 In con-
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Fig 5. Immunohistological analysis of glucocorticoid receptor (GR) expression and localization. (a–d) Sections were immune-labelled with a
GR-specific antibody (brown) and the nuclei counterstained (pink). (a) Representative images from both groups are shown. Original magnification
920; E, epidermis; PD, papillary dermis; RD, reticular dermis. (b) GR expression at week 0 for responsive patients (n = 12) and nonresponsive
patients (n = 7). (c) Steroid-dependent change in GR expression at weeks 2 and 4. (d) Subcellular GR staining in the epidermis. Higher magnification
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clusion, we here demonstrate, for the first time, that keloid
responsiveness to GCs can be objectively evaluated and is
related to both the initial baseline level of GR and its
downregulation. Early identification of nonresponders using
noninvasive imaging is a promising tool that may stop the
clinician from treating unresponsive cases and can prevent
the potentially harmful side-effects of GC therapy. Alterna-
tive and more effective treatment regimens may be offered
to keloid cases that are considered to be nonresponders to
GC therapy.
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